In March 2019, Zebra-Med announced a collaboration with Apollo Hospitals chain, deploying AI-based tools at scale across India, supported by India-Israel Industrial R and D and Technological Innovation Fund.
Following the deployment of the intracranial hemorrhage, the AI COVID-19 solution will enable future collaboration on additional medical findings, such as tuberculosis.
A year later, Zebra-Med's solution, based on a machine learning algorithm that analyzes computed tomography scans, could help relieve the burden on health systems globally, through earlier diagnoses and more effective triage.
Currently, India has more than 190K confirmed COVID-19 cases and more than 5,000 deaths.
While laboratory testing has served as the first line of diagnostics during the coronavirus crisis, these tests have limited accuracy and do not indicate the state of disease progression.
Zebra-Med's software offers a faster alternative for detection of COVID-19 when PCR testing is unavailable or delayed, monitoring patients with COVID-19, as decision support for the allocation of ER, ICU resources and quantifies the disease burden and its progression.
The AI solution for COVID-19 leverages Zebra-Med's GGO (Ground-Glass Opacities) patented algorithm, which is a dominant imaging feature of COVID-19 pneumonia and modified it to include consolidations and provide an automated indication and quantification of suspected COVID-19 findings on standard chest CTs, both contrast and non-contrast, by measuring the percentage of affected lung-burden volume relative to the entire lung volume, segmentation of the suspected findings, and classification.
Zebra Medical Vision's imaging analytics platform allows healthcare institutions to identify patients at risk of disease and offer improved, preventative treatment pathways, to improve patient care.
The company is funded by Khosla Ventures, Marc Benioff, Intermountain Investment Fund, OurCrowd Qure, Aurum, aMoon, Nvidia and Johnson and Johnson.
Zebra Medical Vision has raised USD 52m in funding to date, and was named a Fast company Top-5 AI and Machine Learning company.
Zebra-Med leads the way in AI FDA cleared products, and is installed in hospitals globally, from Australia to India, Europe to the U.S, and the LATAM region.
Galapagos plans to wind down cell therapy business following strategic review
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Revelation Pharma acquires Acacia Apothecary & Wellness
Viatris receives fifth consecutive recognition on Forbes' annual list of World's Best Employers
INOVIO announces inducement grant to new employee
AbbVie's Allergan Aesthetics announces Natrelle supplier agreement with Vizient
Karyopharm Therapeutics awards inducement grants to new employees
POLYTECH Health & Aesthetics announces Poland expansion
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar